News and Events

News

All categories

Earnings

Press Release

All years

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Reports 2023 Financial Results and Operational Progress

March 28, 2024

Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024

March 21, 2024

Affimed Announces 1-for-10 Reverse Stock Split

March 6, 2024

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

January 8, 2024

Affimed Announces Leadership Change and Organizational Restructuring

January 8, 2024

Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck

January 3, 2024

Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients

December 11, 2023

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

December 11, 2023

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

December 11, 2023

Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24

December 4, 2023

Events

All

Scientific

Investors

There are no events planned at the moment.

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Reports 2023 Financial Results and Operational Progress

Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024

Affimed Announces 1-for-10 Reverse Stock Split

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

Affimed Announces Leadership Change and Organizational Restructuring

Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck

Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24

Events